Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease

Neurology

Volumn 66, Issue 4, 2006, Pages 529-534

  Blandini, F ^a   Sinforiani, E ^a   Pacchetti, C ^a   Samuele, A ^a   Bazzini, E ^a   Zangaglia, R ^a   Nappi, G ^a,d   Martignoni, E ^b,c  

^a C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^b IRCCS   (Italy)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

7 AMINO 4 METHYLCOUMARIN; CABERGOLINE; CASPASE; CASPASE 3; CASPASE 9; COUMARIN DERIVATIVE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; PROTEASOME; ROPINIROLE; UBIQUITIN; UNCLASSIFIED DRUG; ANTIPARKINSON AGENT; CASP3 PROTEIN, HUMAN; CASP9 PROTEIN, HUMAN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CATALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE DURATION; DISEASE MARKER; DISEASE SEVERITY; ENZYME ACTIVATION; FEMALE; HUMAN; MALE; NEUROPATHOLOGY; PARKINSON DISEASE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN AGGREGATION; UBIQUITINATION; BLOOD; ENZYMOLOGY; LYMPHOCYTE; MIDDLE AGED; REFERENCE VALUE;

AGED; ALZHEIMER DISEASE; ANTIPARKINSON AGENTS; CASPASE 3; CASPASE 9; CASPASES; FEMALE; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; PARKINSON DISEASE; PROTEASOME ENDOPEPTIDASE COMPLEX; REFERENCE VALUES;

EID: 33645013396     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000198511.09968.b3     Document Type: Article

References (54)

1. Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature 2003;426:895-899.
2. Betarbet R, Sherer TB, Greenamyre JT. Ubiquitin-proteasome system and Parkinson's diseases. Exp Neurol 2005;191:S17-S27.
3. Song S, Jung YK. Alzheimer's disease meets the ubiquitin-proteasome system. Trends Mol Med 2004;10:565-570.
4. Ardley HC, Hung CC, Robinson PA. The aggravating role of the ubiquitin-proteasome system in neurodegeneration. FEBS Lett 2005;579:571-576.
5. Dimakopoulos AC. Protein aggregation in Alzheimer's disease and other neuropathological disorders. Curr Alzheimer Res 2005;2:19-28.
6. Layfield R, Cavey JR, Lowe J. Role of ubiquitin-mediated proteolysis in the pathogenesis of neurodegenerative disorders. Ageing Res Rev 2003;2:343-356.
7. Kitada T, Mizuno Y. [Molecular pathogenesis of familial Parkinson's disease]. Nippon Rinsho 2000;58:2016-2021.
8. Lansbury PT Jr, Brice A. Genetics of Parkinson's disease and biochemical studies of implicated gene products. Curr Opin Cell Biol 2002;14:653-660.
9. Shimura H, Hattori N, Kubo S, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 2000;25:302-305.
10. McNaught KS, Jenner P. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci Lett 2001;297:191-194.
11. McNaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW. Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol 2003;179:38-46.
12. Fornai F, Lenzi P, Gesi M, et al. Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition. J Neurosci 2003;23:8955-8966.
13. McNaught KS, Bjorklund LM, Belizaire R, Isacson O, Jenner P, Olanow CW. Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport 2002;13:1437-1441.
14. McNaught KS, Mytilineou C, Jnobaptiste R, et al. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J Neurochem 2002;81:301-306.
15. McNaught KS, Perl DP, Brownell AL, Olanow CW. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol 2004;56:149-162.
16. Fornai F, Schluter OM, Lenzi P, et al. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc Natl Acad Sci USA 2005;102:3413-3418.
17. Kalivendi SV, Cunningham S, Kotamraju S, Joseph J, Hillard CJ, Kalyanaraman B. Alpha-synuclein up-regulation and aggregation during MPP+-induced apoptosis in neuroblastoma cells: intermediacy of transferrin receptor iron and hydrogen peroxide. J Biol Chem 2004;279:15240-15247.
18. Lang-Rollin I, Rideout H, Stefanis L. Ubiquitinated inclusions and neuronal cell death. Histol Histopathol 2003;18:509-517.
19. Lang-Rollin I, Vekrellis K, Wang Q, Rideout HJ, Stefanis L. Application of proteasomal inhibitors to mouse sympathetic neurons activates the intrinsic apoptotic pathway. J Neurochem 2004;90:1511-1520.
20. Burke RE, Kholodilov NG. Programmed cell death: does it play a role in Parkinson's disease? Ann Neurol 1998;44:S126-S133.
21. Hirsch EC, Hunot S, Faucheux B, et al. Dopaminergic neurons degenerate by apoptosis in Parkinson's disease. Mov Disord 1999;14:383-385.
22. Hirsch EC, Hunot S, Hartmann A. Mechanism of cell death in experimental models of Parkinson's disease. Funct Neurol 2000;15:229-237.
23. Schapira AH. Causes of neuronal death in Parkinson's disease. Adv Neurol 2001;86:155-162.
24. Tatton NA, Kish SJ. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 1997;77:1037-1048.
25. Tatton NA. Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp Neurol 2000;166:29-43.
26. Tatton WG, Chalmers-Redman R, Brown D, Tatton N. Apoptosis in Parkinson's disease: signals for neuronal degradation. Ann Neurol 2003;53:S61-S70.
27. Lopez SM, Morelli L, Castano EM, Soto EF, Pasquini JM. Defective ubiquitination of cerebral proteins in Alzheimer's disease. J Neurosci Res 2000;62:302-310.
28. Keller JN, Hanni KB, Markesbery WR. Impaired proteasome function in Alzheimer's disease. J Neurochem 2000;75:436-439.
29. Ding Q, Keller JN. Does proteasome inhibition play a role in mediating neuropathology and neuron death in Alzheimer's disease? J Alzheimer Dis 2003;5:241-245.
30. Ivins KJ, Thornton PL, Rohn TT, Cotman CW. Neuronal apoptosis induced by beta-amyloid is mediated by caspase-8. Neurobiol Dis 1999;6:440-449.
31. Gervais FG, Xu D, Robertson GS, et al. Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell 1999;97:395-406.
32. Ayala-Grosso C, Ng G, Roy S, Robertson GS. Caspase-cleaved amyloid precursor protein in Alzheimer's disease. Brain Pathol 2002;12:430-441.
33. Cotman CW, Poon WW, Rissman RA, Blurton-Jones M. The role of caspase cleavage of tau in Alzheimer disease neuropathology. J Neuropathol Exp Neurol 2005;64:104-112.
34. Rohn TT, Rissman RA, Davis MC, Kim YE, Cotman CW, Head E. Caspase-9 activation and caspase cleavage of tau in the Alzheimer's disease brain. Neurobiol Dis 2002;11:341-354.
35. Migliore L, Petrozzi L, Lucetti C, et al. Oxidative damage and cytogenetic analysis in leukocytes of Parkinson's disease patients. Neurology 2002;58:1809-1815.
36. Blandini F, Cosentino M, Mangiagalli A, et al. Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson's disease. The effect of dopaminergic treatment. J Neural Transm 2004;111:1017-1030.
37. Tacconi S, Perri R, Balestrieri E, et al. Increased caspase activation in peripheral blood mononuclear cells of patients with Alzheimer's disease. Exp Neurol 2004;190:254-262.
38. Mecocci P, Polidori MC, Cherubini A, et al. Lymphocyte oxidative DNA damage and plasma antioxidants in Alzheimer disease. Arch Neurol 2002;59:794-798.
39. Morocz M, Kalman J, Juhasz A, et al. Elevated levels of oxidative DNA damage in lymphocytes from patients with Alzheimer's disease. Neurobiol Aging 2002;23:47-53.
40. Kadioglu E, Sardas S, Asian S, Isik E, Esat KA. Detection of oxidative DNA damage in lymphocytes of patients with Alzheimer's disease. Biomarkers 2004;9:203-209.
41. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939-944.
42. Musicco M, Sorbi S, Bonavita V, Caltagirone C. Validation of the Guidelines for the Diagnosis of Dementia and Alzheimer's Disease of the Italian Neurological Society. Study in 72 Italian neurological centres and 1549 patients. Neurol Sci 2004;25:289-295.
43. Martignoni E, Blandini F, Godi L, et al. Peripheral markers of oxidative stress in Parkinson's disease. The role of L-DOPA. Free Radic Biol Med 1999;27:428-437.
44. Robertson JD, Orrenius S. Molecular mechanisms of apoptosis induced by cytotoxic chemicals. Crit Rev Toxicol 2000;30:609-627.
45. Hartmann A, Hunot S, Michel PP, et al. Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci USA 2000;97:2875-2880.
46. Hartmann A, Troadec JD, Hunot S, et al. Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis. J Neurosci 2001;21:2247-2255.
47. Mogi M, Togari A, Kondo T, et al. Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from parkinsonian brain. J Neural Transm 2000;107:335-341.
48. Hartmann A, Michel PP, Troadec JD, et al. Is Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease? J Neurochem 2001;76:1785-1793.
49. Anglade P, Vyas S, Javoy-Agid F, et al. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol 1997;12:25-31.
50. Mochizuki H, Goto K, Mori H, Mizuno Y. Histochemical detection of apoptosis in Parkinson's disease. J Neurol Sci 1996;137:120-123.
51. Hong SJ, Dawson TM, Dawson VL. Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. Trends Pharmacol Sci 2004;25:259-264.
52. Donovan M, Cotter TG. Control of mitochondrial integrity by Bcl-2 family members and caspase-independent cell death. Biochim Biophys Acta 2004;1644:133-147.
53. Bidere N, Senik A. Caspase-independent apoptotic pathways in T lymphocytes: a minireview. Apoptosis 2001;6:371-375.
54. Zana M, Juhasz A, Rimanoczy A, et al. Alzheimer's lymphocytes are resistant to ultraviolet B-induced apoptosis. Neurobiol Aging 2005 [Epub ahead of print].